Your browser is no longer supported. Please, upgrade your browser.
Settings
SHPG Shire plc daily Stock Chart
SHPG [NASD]
Shire plc
Index- P/E6.12 EPS (ttm)21.89 Insider Own0.10% Shs Outstand302.04M Perf Week5.20%
Market Cap40.49B Forward P/E7.96 EPS next Y16.85 Insider Trans0.00% Shs Float302.04M Perf Month-7.98%
Income6.63B PEG0.61 EPS next Q3.62 Inst Own20.40% Short Float0.80% Perf Quarter-4.26%
Sales15.16B P/S2.67 EPS this Y-65.50% Inst Trans-3.42% Short Ratio1.90 Perf Half Y-9.39%
Book/sh107.98 P/B1.24 EPS next Y8.27% ROA1.00% Target Price201.79 Perf Year-24.98%
Cash/sh- P/C- EPS next 5Y10.03% ROE2.20% 52W Range123.73 - 192.15 Perf YTD-13.58%
Dividend1.05 P/FCF- EPS past 5Y-12.80% ROI2.10% 52W High-30.23% Beta1.39
Dividend %0.78% Quick Ratio0.50 Sales past 5Y22.30% Gross Margin69.00% 52W Low8.35% ATR3.64
Employees23906 Current Ratio1.00 Sales Q/Q7.10% Oper. Margin8.00% RSI (14)41.83 Volatility2.22% 2.41%
OptionableYes Debt/Eq0.63 EPS Q/Q247.70% Profit Margin4.50% Rel Volume0.71 Prev Close135.30
ShortableYes LT Debt/Eq0.55 EarningsFeb 14 BMO Payout39.80% Avg Volume1.27M Price134.06
Recom1.90 SMA20-3.29% SMA50-8.30% SMA200-13.96% Volume944,332 Change-0.92%
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $201 → $181
Feb-14-18Upgrade Bernstein Mkt Perform → Outperform
Dec-20-17Downgrade Liberum Buy → Hold
Nov-14-17Upgrade Liberum Hold → Buy
Oct-19-17Initiated FBR & Co. Buy $201
Oct-11-17Reiterated RBC Capital Mkts Outperform $213
Aug-17-17Initiated Evercore ISI Outperform $196
Jun-16-17Initiated Cantor Fitzgerald Overweight $222
Jun-09-17Reiterated Jefferies Buy $239 → $216
Jun-01-17Downgrade Liberum Buy → Hold
May-26-17Downgrade Bernstein Outperform → Mkt Perform
May-19-17Downgrade HSBC Securities Hold → Reduce
Mar-09-17Initiated Liberum Buy
Dec-02-16Initiated Societe Generale Buy
Sep-26-16Downgrade HSBC Securities Buy → Hold
Jun-03-16Reiterated Jefferies Buy $223 → $262
May-26-16Initiated Stifel Buy $230
May-06-16Initiated Liberum Buy
Feb-26-16Initiated Cantor Fitzgerald Buy
Feb-10-16Upgrade RBC Capital Mkts Sector Perform → Outperform $240 → $240
Feb-15-18 01:09PM  With A Recent ROE Of 4.97%, Can Shire plc (NASDAQ:SHPG) Catch Up To Its Industry? Simply Wall St.
09:30AM  Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong Zacks
07:01AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Feb-14-18 10:54AM  Shire sees slowdown in earnings growth as generic rivals bite Reuters
09:11AM  Shire beats Street 4Q forecasts Associated Press
07:16AM  Shire posts 16 pct rise in full-year earnings, sees slower growth in 2018 Reuters
07:01AM  Shire plc : Final Results GlobeNewswire
12:47AM  [$$] Shire warns on competition from generic drugs Financial Times
Feb-12-18 09:59AM  Shire (SHPG) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-05-18 06:07AM  Is Shire plcs (LON:SHP) PE Ratio A Signal To Buy For Investors? Simply Wall St. -5.85%
Feb-04-18 04:11PM  Stocks That Fell to 3-Year Lows in the Week of Feb. 2 GuruFocus.com
Feb-01-18 09:01AM  Shire plc : Notice of Results GlobeNewswire
08:01AM  Shire plc : Total voting rights GlobeNewswire
07:20AM  Wired News Shire Secured Exclusive Worldwide License to Develop and Commercialize AB Biosciences PRIM Program ACCESSWIRE
Jan-30-18 07:01AM  AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program GlobeNewswire
Jan-29-18 09:47AM  Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ Zacks
Jan-25-18 10:29AM  Shire Gets FDA Nod for Cinryze Tech Transfer to New Site Zacks
Jan-24-18 09:00AM  Will Sanofi's Big Hemophilia Deal Pay Off? Motley Fool
06:01AM  FDA Grants Approval to Shire for Technology Transfer of CINRYZE® Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site GlobeNewswire
Jan-19-18 05:01AM  Shire plc : Directorate change GlobeNewswire
Jan-11-18 09:04AM  How Is Bioverativs Alprolix Positioned Now? Market Realist
07:35AM  How Is Bioverativs Eloctate Positioned Now? Market Realist
07:33AM  How Is Roches Hemlibra Positioned for 2018? Market Realist
Jan-08-18 06:01PM  Full interview with Shire CEO Flemming Ørnskov CNBC Videos
01:44PM  Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs Reuters
12:55PM  Shire cuts sales outlook; still considering spinout of ADHD drugs American City Business Journals
10:15AM  Shire to separate ADHD drugs before possible spin-off, cuts 2020 target Reuters
09:31AM  Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-05-18 10:35AM  How Novo Nordisks Biopharmaceuticals Segment Performed in 3Q17 Market Realist
09:46AM  Future of Kala Pharma's dry eye drug uncertain after mixed results Reuters
Jan-04-18 07:01AM  Shire to present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-18 08:01AM  Shire plc : Total voting rights GlobeNewswire
05:01AM  Shire plc : Director Declaration GlobeNewswire
Jan-01-18 09:19AM  Shire Plc :SHPG-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-28-17 09:11AM  Protalix (PLX) Fabry Disease Candidate Gets Orphan Status Zacks
06:00AM  Healthcare: Pick Carefully as Valuations Head Higher Morningstar
Dec-27-17 11:54AM  Shire: If You Build It Barrons.com
11:48AM  ETFs with exposure to Shire Plc : December 27, 2017 Capital Cube
07:01AM  Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise GlobeNewswire
Dec-25-17 08:27AM  Will Shire plcs (LON:SHP) Earnings Grow Over The Next Few Years? Simply Wall St.
Dec-22-17 07:00AM  Rare-Disease Portfolio Digs Shire a Moat Morningstar
Dec-21-17 07:15AM  Shire plc (NASDAQ:SHPG): What Can We Expect From This High Growth Stock? Simply Wall St.
Dec-20-17 07:31AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Dec-19-17 08:11AM  Shire's Hunter syndrome drug fails late-stage study Reuters
07:38AM  Shire's stock falls after drug trial misses primary and secondary endpoints MarketWatch
07:27AM  Shire says Hunter syndrome treatment fails in key study Reuters
07:01AM  Shire plc : Director Declaration GlobeNewswire
Dec-16-17 04:57AM  Roche, Shire court fight escalates over haemophilia drug Reuters
Dec-14-17 10:09AM  Shire's New Formulation of Oncaspar Gets Approval in Europe Zacks
Dec-13-17 02:26AM  Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) GlobeNewswire
Dec-12-17 12:07PM  This Porridge Is Too Hot: Valeant Bears Abandon the Stock Barrons.com
Dec-08-17 11:01AM  Shire plc : Directorate change GlobeNewswire
Dec-07-17 07:10AM  Wired News Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill Technology ACCESSWIRE
Dec-05-17 10:52AM  Shire and Rani Therapeutics Enter into Collaboration to Evaluate Use of the Rani Pill(TM) Technology for the Oral Delivery of Factor Therapy GlobeNewswire
09:01AM  Shire in deal to develop a new way to administer hemophilia drug Reuters
05:47AM  How Financially Strong Is Shire plc (LSE:SHP)? Simply Wall St.
Dec-01-17 07:31AM  Shire plc : Total voting rights GlobeNewswire
03:01AM  Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer GlobeNewswire
Nov-30-17 07:01AM  U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric Patients GlobeNewswire
Nov-25-17 07:08AM  Shire plc : Block listing Interim Review GlobeNewswire
Nov-20-17 11:40AM  Is Shire Bleeding Out? Barrons.com
08:01AM  Shire plc : Directorate change GlobeNewswire
07:05AM  Why Shire plc (LSE:SHP) Could Be A Buy Simply Wall St.
Nov-17-17 09:05AM  Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval Zacks
Nov-14-17 10:09AM  Shire Gets Positive CHMP Opinion for Hemophilia A Drug Zacks
Nov-13-17 01:01AM  CHMP recommends EU marketing authorization for ADYNOVI® for adults and adolescents with Hemophilia A GlobeNewswire
Nov-10-17 07:01AM  Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology GlobeNewswire
Nov-07-17 06:02AM  The Only 3 Big Pharma Companies Growing Market Share Motley Fool
Nov-03-17 12:32PM  ETFs with exposure to Shire Plc : November 3, 2017 Capital Cube
06:01AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Nov-02-17 10:03AM  FTSE gains after dovish BoE rate hike, domestic banks drop Reuters
07:50AM  Earnings Review and Free Research Report: Eli Lillys Adjusted EPS Increased 19% ACCESSWIRE
Nov-01-17 08:02AM  Shire plc : Total voting rights GlobeNewswire
Oct-30-17 11:53AM  Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong Zacks
05:49AM  Fund manager, analysts make the case for this loathed pharma stock MarketWatch
Oct-27-17 01:05PM  Shire to sell 100-employee Milford site as part of manufacturing slim-down American City Business Journals
11:01AM  Shire to make genetic disease drug itself to secure supply Reuters
07:28AM  Shire beats 3Q profit forecasts Associated Press
07:02AM  Shire plc : 3rd Quarter Results GlobeNewswire
Oct-26-17 12:16PM  Allergan (AGN) to Report Q3 Earnings: What's in the Cards? Zacks
02:02AM  Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients GlobeNewswire
Oct-25-17 07:01AM  Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A GlobeNewswire
Oct-23-17 11:03AM  ETFs with exposure to Shire Plc : October 23, 2017 Capital Cube
Oct-19-17 09:18AM  Create the Soundtrack to Your Unique Day with "Compose Your Life" PR Newswire
Oct-17-17 09:27AM  Why Shire plc (LSE:SHP) Delivered An Inferior ROE Compared To The Industry Simply Wall St.
Oct-16-17 10:02AM  Shire's New Formulation of Oncaspar Gets CHMP Recommendation Zacks
Oct-13-17 02:06AM  Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) GlobeNewswire
Oct-10-17 11:49AM  ETFs with exposure to Shire Plc : October 10, 2017 Capital Cube
Oct-09-17 09:54AM  Shire Plc :SHPG-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017 Capital Cube
Oct-05-17 07:02AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Oct-03-17 07:02AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
01:04AM  Shire Alleges Allergan Blocked Drug From Medicare Contracts The Wall Street Journal
Oct-02-17 02:00PM  Shire Alleges Allergan Blocked Drug From Medicare Contracts The Wall Street Journal
12:14PM  Shire sues Allergan in U.S. over dry eye drug Reuters
09:02AM  Shire plc : Total voting rights GlobeNewswire
Sep-29-17 10:36AM  Should You Sell Shire plc (LSE:SHP) At £37.78? Simply Wall St.
09:32AM  Shire Plc : SHPG-US: Dividend Analysis : September 08th, 2017 (record date) : By the numbers : September 29, 2017 Capital Cube
Sep-25-17 11:42AM  Why Allergan is Jumping Barrons.com
Sep-21-17 09:50AM  Is Shire plc (SHPG) a Suitable Value Stock? Zacks
Sep-18-17 10:00AM  Neos Therapeutics ADHD Drug Adzenys Receives Approval in US Zacks
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.